Where Is the Diagnostics Market Heading? 10 Promising Sectors to Watch

29 Oct 2026 • by Natalie Aster

Nowadays, the diagnostics market is moving beyond isolated laboratory tests. The fastest-developing platforms combine biomarkers, imaging, sequencing, sensors, and clinical software to identify disease earlier and link results directly to treatment. Near-term growth will concentrate where regulatory progress, installed laboratory infrastructure, and a clear clinical use case already intersect.

The opportunity is not evenly distributed. Platforms that merely produce more data may struggle to secure reimbursement or clinical adoption. The likely winners will reduce diagnostic uncertainty, shorten turnaround times, eliminate unnecessary procedures, or identify patients for a specific therapy. Those requirements are reshaping investment across the following ten sectors.

1. AI-Powered Diagnostic Software

Artificial intelligence is becoming part of routine diagnostic workflow rather than a separate experimental tool. Roche’s 2026 Liver Disease Panel illustrates the shift toward certified algorithms that combine laboratory and clinical data inside existing hospital systems. Commercial success will depend on integration, measurable time savings, and transparent validation. 

The most valuable products will not attempt to replace clinicians. They will calculate risk, prioritize complex cases, detect inconsistencies, and transform several measurements into one actionable assessment. Developers must still address data quality, performance across different patient populations, cybersecurity, and monitoring after deployment – particularly when models are updated.

2. Comprehensive Liquid Biopsy

Liquid biopsy is expanding from narrow mutation testing to multiomic tumor profiling. In May 2026, the FDA approved Guardant360 Liquid CDx, which integrates genomic and epigenomic signals and examines a substantially broader genomic footprint. Blood-based testing is therefore becoming more useful when tissue is limited or repeated monitoring is required.

The commercial opportunity extends across therapy selection, resistance detection, recurrence surveillance, and treatment-response monitoring. Repeated blood collection is less burdensome than repeated tissue biopsy and can capture molecular changes occurring across several tumor sites. However, sensitivity at very low tumor fractions and interpretation of negative results remain important clinical limitations.

3. Multi-Cancer Early Detection Tests

Multi-cancer early detection reached a regulatory inflection point in September 2026, when an FDA advisory committee reviewed GRAIL’s Galleri premarket application. The test searches for cancer-specific methylation patterns and predicts the likely tissue of origin. Approval is not assured, but the review moves this category closer to mainstream screening.

If clinically and economically validated, multi-cancer tests could create a new screening layer for malignancies that lack established population programs. The central challenge is not simply detecting a signal: health systems need efficient confirmation pathways that control false positives, diagnostic imaging demand, patient anxiety, and the risk of finding indolent disease.

4. Alzheimer’s Blood Biomarkers

Neurodegenerative testing is shifting toward scalable blood assays. Roche received a CE mark in May 2026 for its Elecsys pTau217 test, designed to identify Alzheimer’s-related amyloid pathology in people with early cognitive decline. Compatibility with widely installed analyzers could accelerate adoption and reduce dependence on PET imaging and cerebrospinal-fluid testing.

This sector is gaining strategic importance because emerging Alzheimer’s treatment pathways require evidence of underlying pathology. Blood testing can support specialist referral, rule-in or rule-out strategies, and selection for confirmatory examinations. Laboratory automation also creates a realistic route from highly specialized testing toward broader neurology and memory-clinic use.

5. Precision-Oncology Companion Diagnostics

Companion diagnostics are evolving from one-time treatment selection to longitudinal disease management. A September 2026 FDA approval allowed Guardant360 CDx to detect emerging ESR1 mutations before radiographic progression in advanced breast cancer, creating a model in which molecular change can trigger an earlier therapy switch.

This approach could expand the addressable market for testing because a patient may be assessed at diagnosis and repeatedly during treatment. Growth will follow the pipeline of biomarker-defined medicines, but diagnostic developers must coordinate assay validation, clinical trials, regulatory submissions, and commercialization with pharmaceutical partners – often before the associated therapy reaches the market.

6. Whole-Genome & Rare-Disease Diagnostics

Whole-genome sequencing is moving closer to standardized clinical deployment. Illumina launched TruPath Genome in 2026 to support rapid, comprehensive investigation of rare genetic conditions. Growth will come from reducing diagnostic odysseys, consolidating multiple sequential tests, and connecting genomic findings with precision-treatment options.

The strongest use cases include critically ill children, unresolved inherited disorders, reproductive genetics, and complex neurological conditions. Sequencing cost is only one component of adoption. Laboratories also require automated interpretation, curated variant databases, secure data infrastructure, genetic counselling capacity, and procedures for reanalysis when scientific knowledge changes.

7. Continuous Metabolic Biosensors

Continuous monitoring is expanding beyond glucose. In August 2026, the FDA authorized Abbott’s Libre Duo 10 Day, the first integrated system to monitor glucose and ketones continuously. Multi-analyte biosensors can turn episodic measurements into early-warning systems for acute and chronic metabolic risk.

The next competitive frontier is the interpretation layer rather than the sensor alone. Alerts must distinguish clinically meaningful deterioration from normal variation without overwhelming users. Integration with insulin delivery, nutrition services, telehealth, and clinician dashboards could extend continuous diagnostics into preventive metabolic care and remote management of higher-risk patients.

8. Point-of-Care & Decentralized Testing

Point-of-care diagnostics are advancing toward broader test menus, automated interpretation, and connectivity with clinical records. Demand is strongest where a result can immediately change triage, isolation, or prescribing. Compact molecular systems, automated urine analysis, and digitally connected immunoassays will bring more testing outside central laboratories.

Urgent care centres, pharmacies, ambulances, community clinics, and resource-constrained settings represent major expansion channels. The key purchasing criteria are short hands-on time, low error rates, simple quality control, and results that can flow directly into medical records. Multiplex assays will be especially valuable when several conditions produce similar symptoms.

9. AI-Enabled Digital Pathology

Digital pathology is becoming an operational platform for cancer diagnosis. In April 2026, Paige’s PanCancer Detect received FDA Breakthrough Device designation for detecting suspicious cancer foci across multiple tissues. The product remains research-use-only, but it illustrates how the next commercial phase could combine whole-slide imaging, case prioritization, biomarker quantification, and remote review.

Adoption requires more than purchasing slide scanners. Laboratories need image storage, interoperability, validated displays, cybersecurity, and redesigned workflows that prevent digital backlogs. Once that infrastructure is established, the same platform can support remote consultations, quality assurance, clinical trials, computational biomarker development, and multiple AI applications.

10. Advanced Diagnostic Imaging

Imaging growth is shifting toward photon-counting CT, hybrid modalities, contrast-enhanced mammography, and real-time AI reconstruction. Siemens Healthineers opened a dedicated photon-counting sensor facility in September 2026, signalling preparation for wider deployment of higher-resolution CT systems with improved material differentiation.

Photon-counting detectors measure individual X-ray photons and their energy rather than relying on conventional energy-integrating detection. The technology can improve spatial resolution and spectral information while supporting more precise tissue characterization. Adoption will initially favour centres where added diagnostic information can justify equipment, infrastructure, and training costs.

Final Thoughts

The strongest diagnostics markets are no longer defined by test volume alone. Value is moving toward platforms that detect disease sooner, generate several layers of information from one sample, and deliver a result that changes patient management. Through the next several years, regulatory evidence, reimbursement, workflow integration, and access to clinical data will determine which technologies scale fastest.

The common direction is clear: diagnostics are becoming continuous rather than episodic, multi-analyte rather than single-marker, and directly connected to therapeutic decisions. Companies that can demonstrate clinical utility, not merely analytical performance, will be better positioned to secure reimbursement, build physician confidence, and convert promising technology into repeatable demand through 2030.

At Market Publishers you’ll find a rich collection of insightful research studies featuring various markets. Simply use the search form to find the report you need.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +357 96 030 922
 [email protected]
 MarketPublishers.com